Literature DB >> 16098468

Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer.

Sungwoo Lee1, Eijiro Nakamura, Haifeng Yang, Wenyi Wei, Michelle S Linggi, Mini P Sajan, Robert V Farese, Robert S Freeman, Bruce D Carter, William G Kaelin, Susanne Schlisio.   

Abstract

Germline NF1, c-RET, SDH, and VHL mutations cause familial pheochromocytoma. Pheochromocytomas derive from sympathetic neuronal precursor cells. Many of these cells undergo c-Jun-dependent apoptosis during normal development as NGF becomes limiting. NF1 encodes a GAP for the NGF receptor TrkA, and NF1 mutations promote survival after NGF withdrawal. We found that pheochromocytoma-associated c-RET and VHL mutations lead to increased JunB, which blunts neuronal apoptosis after NGF withdrawal. We also found that the prolyl hydroxylase EglN3 acts downstream of c-Jun and is specifically required among the three EglN family members for apoptosis in this setting. Moreover, EglN3 proapoptotic activity requires SDH activity because EglN3 is feedback inhibited by succinate. These studies suggest that failure of developmental apoptosis plays a role in pheochromocytoma pathogenesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16098468     DOI: 10.1016/j.ccr.2005.06.015

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  184 in total

1.  Prolyl hydroxylase PHD3 enhances the hypoxic survival and G1 to S transition of carcinoma cells.

Authors:  Heidi Högel; Krista Rantanen; Terhi Jokilehto; Reidar Grenman; Panu M Jaakkola
Journal:  PLoS One       Date:  2011-11-08       Impact factor: 3.240

Review 2.  Cellular metabolism and disease: what do metabolic outliers teach us?

Authors:  Ralph J DeBerardinis; Craig B Thompson
Journal:  Cell       Date:  2012-03-16       Impact factor: 41.582

Review 3.  An update on the genetics of pheochromocytoma.

Authors:  D Karasek; U Shah; Z Frysak; C Stratakis; K Pacak
Journal:  J Hum Hypertens       Date:  2012-05-31       Impact factor: 3.012

4.  von Hippel-Lindau mutation in mice recapitulates Chuvash polycythemia via hypoxia-inducible factor-2alpha signaling and splenic erythropoiesis.

Authors:  Michele M Hickey; Jennifer C Lam; Natalie A Bezman; W Kimryn Rathmell; M Celeste Simon
Journal:  J Clin Invest       Date:  2007-12       Impact factor: 14.808

5.  Ribozyme-mediated targeting of IkappaBgamma inhibits melanoma invasion and metastasis.

Authors:  Sima Z Torabian; David de Semir; Mehdi Nosrati; Sepideh Bagheri; Altaf A Dar; Sylvia Fong; Yong Liu; Scot Federman; Jeff Simko; Chris Haqq; Robert J Debs; Mohammed Kashani-Sabet
Journal:  Am J Pathol       Date:  2009-01-29       Impact factor: 4.307

Review 6.  Current and future therapeutic approaches for metastatic pheochromocytoma and paraganglioma: focus on SDHB tumors.

Authors:  J Matro; A Giubellino; K Pacak
Journal:  Horm Metab Res       Date:  2013-01-15       Impact factor: 2.936

7.  EglN3 hydroxylase stabilizes BIM-EL linking VHL type 2C mutations to pheochromocytoma pathogenesis and chemotherapy resistance.

Authors:  Shuijie Li; Javier Rodriguez; Wenyu Li; Petra Bullova; Stuart M Fell; Olga Surova; Isabelle Westerlund; Danijal Topcic; Maria Bergsland; Adam Stenman; Jonas Muhr; Monica Nistér; Johan Holmberg; C Christofer Juhlin; Catharina Larsson; Alex von Kriegsheim; William G Kaelin; Susanne Schlisio
Journal:  Proc Natl Acad Sci U S A       Date:  2019-08-02       Impact factor: 11.205

8.  Neuropeptide Y expression in phaeochromocytomas: relative absence in tumours from patients with von Hippel-Lindau syndrome.

Authors:  Susannah Cleary; Jacqueline K Phillips; Thanh-Truc Huynh; Karel Pacak; Abdel G Elkahloun; Jennifer Barb; Robert A Worrell; David S Goldstein; Graeme Eisenhofer
Journal:  J Endocrinol       Date:  2007-05       Impact factor: 4.286

9.  Personalized medicine: the future is not what it used to be.

Authors:  Michael J Demeure
Journal:  Surgery       Date:  2009-12       Impact factor: 3.982

10.  Prolyl hydroxylase EGLN3 regulates skeletal myoblast differentiation through an NF-kappaB-dependent pathway.

Authors:  Jian Fu; Mark B Taubman
Journal:  J Biol Chem       Date:  2010-01-10       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.